Title: Partially Balanced Incomplete Block Designs
Description: Assists in calculating the efficiencies of Partially Balanced Incomplete Block Designs with any number of associate classes. This will help the researchers in calculating the efficiencies of their PBIB designs very quickly and efficiently.

Description: It constructs four series of PBIB designs and also assists in calculating the efficiencies of PBIB Designs with any number of associate classes. This will help the researchers in adopting a PBIB designs and calculating the efficiencies of any PBIB design very quickly and efficiently.

Description: The PBIB designs are important type of incomplete block designs having wide area of their applications for example in agricultural experiments, in plant breeding, in sample surveys etc. This package constructs various series of PBIB designs and assists in checking all the necessary conditions of PBIB designs and the association scheme on which these designs are based on. It also assists in calculating the efficiencies of PBIB designs with any number of associate classes. The package also constructs Youden-m square designs which are Row-Column designs for the two-way elimination of heterogeneity. The incomplete columns of these Youden-m square designs constitute PBIB designs. With the present functionality, the package will be of immense importance for the researchers as it will help them to construct PBIB designs, to check if their PBIB designs and association scheme satisfy various necessary conditions for the existence, to calculate the efficiencies of PBIB designs based on any association scheme and to construct Youden-m square designs for the two-way elimination of heterogeneity. R. C. Bose and K. R. Nair (1939) <http://www.jstor.org/stable/40383923>.

Title: Estimating the Probability of Being in Response and Related
Description: Make statistical inference on the probability of being in response,
the duration of response, and the cumulative response rate up to a given time point.
The method can be applied to analyze phase II randomized clinical trials with the endpoints
being time to treatment response and time to progression or death.